inmune bio inc. is a clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. inkmune, the company’s lead product, primes patient’s nk cells (natural killer cells) to kill cancer. inmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. by controlling residual disease, patients may live longer. using a novel mechanism of action and a precision medicine approach, inkmune therapy should enhance nk cells’ ability to eliminate residual disease.
Company profile
Ticker
INMB
Exchange
Website
CEO
Raymond J. Tesi
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
INmune Bio International Ltd. • INmune Bio Australia Pty Ltd • DN02, Inc. ...
IRS number
475205835
INMB stock data
Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
9 May 24
S-3
Shelf registration
1 May 24
8-K
Other Events
30 Apr 24
8-K
INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
26 Apr 24
424B5
Prospectus supplement for primary offering
26 Apr 24
8-K
Other Events
25 Apr 24
8-K
Entry into a Material Definitive Agreement
22 Apr 24
424B5
Prospectus supplement for primary offering
22 Apr 24
10-K/A
2023 FY
Annual report (amended)
16 Apr 24
8-K
INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024
9 Apr 24
Transcripts
INMB
Earnings call transcript
2023 Q4
28 Mar 24
INMB
Earnings call transcript
2023 Q3
1 Nov 23
INMB
Earnings call transcript
2023 Q2
7 Aug 23
INMB
Earnings call transcript
2023 Q1
3 May 23
INMB
Earnings call transcript
2022 Q4
2 Mar 23
INMB
Earnings call transcript
2022 Q3
2 Nov 22
INMB
Earnings call transcript
2022 Q2
4 Aug 22
INMB
Earnings call transcript
2022 Q1
8 May 22
INMB
Earnings call transcript
2021 Q4
4 Mar 22
INMB
Earnings call transcript
2021 Q3
4 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 41.81 mm | 41.81 mm | 41.81 mm | 41.81 mm | 41.81 mm | 41.81 mm |
Cash burn (monthly) | 2.00 mm | 1.30 mm | 2.84 mm | 2.25 mm | 1.42 mm | 1.19 mm |
Cash used (since last report) | 14.76 mm | 9.57 mm | 20.94 mm | 16.57 mm | 10.47 mm | 8.76 mm |
Cash remaining | 27.05 mm | 32.24 mm | 20.88 mm | 25.24 mm | 31.34 mm | 33.05 mm |
Runway (months of cash) | 13.5 | 24.8 | 7.3 | 11.2 | 22.1 | 27.8 |
Institutional ownership, Q4 2023
10.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 6 |
Opened positions | 1 |
Closed positions | 31 |
Increased positions | 1 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 804.83 mm |
Total shares | 1.96 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
XNCR Xencor | 1.89 mm | $0.00 |
Westside Investment Management | 41.87 k | $471.40 mm |
Fermata Advisors | 29.43 k | $331.34 mm |
Valley National Advisers | 1.00 k | $11.00 k |
IFP Advisors | 184.00 | $2.07 mm |
FNY Investment Advisers | 100.00 | $1.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
19 Apr 24 | Lowdell Mark William | Common Stock | Grant | Acquire A | No | No | 8.32 | 14,423 | 120.00 k | 1,510,806 |
19 Apr 24 | Lowdell Mark William | Common Stock Warrants Common Stock | Grant | Acquire A | No | No | 0.125 | 14,423 | 1.80 k | 14,423 |
19 Apr 24 | Scott Juda | Common Stock | Grant | Acquire A | No | No | 8.32 | 29,603 | 246.30 k | 66,603 |
19 Apr 24 | Scott Juda | Common Stock Warrants Common Stock | Grant | Acquire A | No | No | 0.125 | 29,603 | 3.70 k | 29,603 |
19 Apr 24 | Tesi Raymond Joseph | Common Stock | Grant | Acquire A | No | No | 8.32 | 18,028 | 149.99 k | 1,538,726 |
19 Apr 24 | Tesi Raymond Joseph | Common Stock Warrants Common Stock | Grant | Acquire A | No | No | 0.125 | 18,028 | 2.25 k | 18,028 |
19 Apr 24 | Moss David J | Common Stock | Buy | Acquire P | No | No | 8.32 | 18,028 | 149.99 k | 1,268,179 |
19 Apr 24 | Moss David J | Common Stock Warrants Common Stock | Buy | Acquire P | No | No | 0.125 | 18,028 | 2.25 k | 18,028 |
News
INmune Bio Q1 2024 GAAP EPS $(0.61) Misses $(0.54) Estimate, Sales $14.000K Miss $30.000K Estimate
9 May 24
INmune Bio Inc. Presents Data On INB03's Role As An Immune Check Point Modulator In The Treatment Of High-Risk Breast Cancer At AACR 2024
8 Apr 24
INmune Bio: Q4 Earnings Insights
28 Mar 24
INmune Bio Q4 EPS $(0.47) Misses $(0.44) Estimate, Sales $28.00K Miss $40.00K Estimate
28 Mar 24
Earnings Scheduled For March 28, 2024
28 Mar 24